Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Exploring chemotherapy-free induction treatment for patients with Ph+ ALL

Robin Foà • 11 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Dasatinib
GIMEMA LAL2116

Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discusses opportunities for a chemotherapy-free frontline induction treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Prof. Foà first discusses results from the GIMEMA LAL2116 trial (NCT02744768) evaluating the use of frontline dasatinib followed by blinatumomab in Ph+ ALL, and then goes on to discuss the importance of reducing the use of chemotherapy-based regimens in this disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Robin Foà

5:14
Is transplantation and chemotherapy still necessary for all patients with Ph+ ALL?
Robin Foà • 15 Apr 2024
8:11
The José Carreras award and a history of immunotherapy in Ph+ ALL
Robin Foà • 11 Jun 2023
3:22
The evolution of therapy for Ph+ ALL and Ph- ALL & the role of MRD in this space
Robin Foà • 11 Jun 2023
2:36
Investigating the incidence and outcomes of CNS relapse in patients with ALL
Robin Foà • 23 Mar 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals